ImmunityBio stock price surges on ANKTIVA sales pop — what IBRX investors watch next
New York, Jan 17, 2026, 06:10 EST — Markets have closed for the day.
Shares of ImmunityBio Inc (IBRX.O) surged almost 40% on Friday following a strong boost in preliminary sales for its bladder cancer treatment ANKTIVA, alongside fresh trial updates. The stock finished at $5.52, marking a 39.9% gain, after swinging between $4.09 and $6.44 on heavy volume of roughly 182 million shares.
The rally is significant as ImmunityBio works to show ANKTIVA can shift from a niche debut to consistent commercial success. Investors are also focused on whether the drug can tap into a broader first-line bladder cancer market—something that would reshape the revenue trajectory.
U.S. stock markets were closed Monday for Martin…
